Johnson & Johnson quarterly profit jumps 32%
Published
Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
Full ArticlePublished
Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
Full Article